The compound you're describing, 1-(2,6-dimethyl-1H-indol-3-yl)-2-(1-pyrrolidinyl)ethanone, is a synthetic molecule often called **Indoximod**. It's not a naturally occurring substance but has gained significant interest in research due to its potential therapeutic applications, primarily as an **immunomodulator**.
**Here's why it's important for research:**
* **Immune System Stimulation:** Indoximod acts as a **toll-like receptor 7 (TLR7) agonist**. TLR7 is a key component of the innate immune system, recognizing viral RNA and triggering immune responses. Indoximod essentially 'tricks' the immune system into thinking a viral infection is present, leading to the production of various immune cells and molecules that can fight infections and cancers.
* **Cancer Therapy:** This immune-stimulating property has made Indoximod a promising candidate for treating various cancers. It's currently being investigated in clinical trials for **advanced melanoma**, **non-small cell lung cancer**, and other types of tumors. The hope is that Indoximod can help the immune system target and destroy cancerous cells.
* **Antiviral Activity:** Indoximod's TLR7 agonistic activity also suggests potential applications in fighting viral infections. It's being researched for its potential to treat **viral hepatitis** and other viral illnesses.
* **Mechanism of Action:** Understanding how Indoximod works can lead to the development of new and improved immunotherapies. Scientists are actively studying the molecule's interactions with TLR7 and the downstream signaling pathways involved in activating the immune system.
**Overall:** Indoximod represents an exciting area of research with potential benefits for treating a wide range of diseases. Its ability to modulate the immune system, particularly through TLR7 activation, offers promising avenues for developing new therapies. However, it's crucial to note that research is ongoing, and the full scope of its applications and potential side effects are still being investigated.
ID Source | ID |
---|---|
PubMed CID | 660165 |
CHEMBL ID | 1511622 |
CHEBI ID | 120959 |
Synonym |
---|
MLS000037422 , |
smr000041084 |
CHEBI:120959 |
1-(2,6-dimethyl-1h-indol-3-yl)-2-pyrrolidin-1-ylethanone |
AKOS005470088 |
STK539730 |
1-(2,6-dimethyl-1h-indol-3-yl)-2-(pyrrolidin-1-yl)ethanone |
HMS2276C15 |
CHEMBL1511622 |
1-(2,6-dimethyl-1h-indol-3-yl)-2-(1-pyrrolidinyl)ethanone |
Q27209167 |
Class | Description |
---|---|
indoles | Any compound containing an indole skeleton. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
15-lipoxygenase, partial | Homo sapiens (human) | Potency | 15.8489 | 0.0126 | 10.6917 | 88.5700 | AID887 |
thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 19.9526 | 0.1000 | 22.9075 | 100.0000 | AID485364 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 89.1251 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.1251 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 125.8920 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
snurportin-1 | Homo sapiens (human) | Potency | 125.8920 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
Vpr | Human immunodeficiency virus 1 | Potency | 31.6228 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |